Extension Study on the Safety and Efficacy of Enteric-coated Mycophenolate Sodium in Kidney Transplant Recipients

Last updated: January 28, 2011
Sponsor: Novartis
Overall Status: Completed

Phase

3

Condition

Kidney Transplantation

Treatment

N/A

Clinical Study ID

NCT00239070
CERL080A2405IN01E1
  • Ages 18-75
  • All Genders

Study Summary

This extension study is to assess the long-term safety of EC-MPS

Eligibility Criteria

Inclusion

Inclusion / Exclusion Criteria - All patients who completed study CERL080A2405-IN01 and who are willing to continue treatment with Enteric-Coated Mycophenolate Sodium.

Other protocol-defined inclusion / exclusion criteria may apply

Study Design

Total Participants: 69
Study Start date:
April 01, 2003
Estimated Completion Date:
May 31, 2006